Annonce • Feb 13
BioGaia AB (publ), Annual General Meeting, May 07, 2026 BioGaia AB (publ), Annual General Meeting, May 07, 2026. Annonce • Oct 13
BioGaia AB (publ) to Report Q3, 2025 Results on Oct 22, 2025 BioGaia AB (publ) announced that they will report Q3, 2025 results at 8:00 AM, Central European Standard Time on Oct 22, 2025 Annonce • Aug 22
BioGaia AB (publ) Elects Mauricio Graber as New Board Member and Chairman of the Board At an extraordinary general meeting of BioGaia AB (publ) on 22 August 2025, it was resolved to elect Mauricio Graber as new board member and chairman of the board, following Peter Rothschild's decision to resign as board member and chairman. Annonce • Jul 25
Biogaia AB (Publ) Announces Resignation of Peter Rothschild as Chairman of the Board and Leave the Board of Directors, Effective At the Extraordinary General Meeting, 22 August 2025 BioGaia AB (publ) announced that Peter Rothschild has announced that he will resign as Chairman of the Board and leave the Board of Directors at the Extraordinary General Meeting, 22 August 2025. Annonce • Mar 21
Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) Annwall & Rothschild Investments Ab, David Dangoor and others entered into an agreement to acquire stake in BioGaia AB (publ) (OM : BIOG B) for SEK 756 million on March 20, 2025. The purchase price amounts to SEK 136.33 for each current class A share and SEK 115 for each class B share. Under the transaction, Anatom will acquire 1,776,758 class A shares and 2,273,600 class B shares (including to-be-converted class A shares) (in total, 4.0% of the total number of shares and 16.0% of the total number votes after the share conversion). The other separate entities, owned by a different member of the Kahane family, will acquire 888,380 class A shares and 1,136,800 class B shares (including to-beconverted class A shares) (in total, 2.0% of the total number of shares and 8.0% of the total number votes after the share conversion).
After the transaction, including existing shareholdings, Anatom will own 1,776,758 class A shares and 5,580,775 class B shares (7.3% of the total number of shares and 18.7% of the total number votes) and the other separate entities, owned by a different member of the Kahane family, will own 888,380 class A shares and 2,809,438 class B shares (3.7% of the total number of shares and 9.3% of the total number votes). The purchase by Anatom is conditional on approval by the Swedish Inspectorate of Strategic Products. Such approval is expected in a few weeks. The Annual General Meeting of BioGaia
The sellers have engaged Rothschild & Co Nordic AB as financial advisor and Vinge as legal advisor in connection with the transaction. Annwall & Rothschild Investments Ab, David Dangoor and others have engaged Gernandt & Danielsson as legal advisor in connection with the transaction. Annonce • Feb 26
BioGaia AB (publ) announces Annual dividend, payable on May 14, 2025 BioGaia AB (publ) announced Annual dividend of SEK 1.9500 per share payable on May 14, 2025, ex-date on May 08, 2025 and record date on May 09, 2025. Annonce • Dec 06
BioGaia Launches A New Probiotic Supplement, BioGaia® Gastrus® PURE ACTION BioGaia announced launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support individuals with sensitive stomachs. This latest addition to BioGaia's product portfolio in adult gut health expands access to specialized advanced, evidence-based solutions for improved digestive health and quality of life. BioGaia® Gastrus® PURE ACTION is formulated with the proprietary, patented probiotic strains L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, carefully selected for their clinically proven efficacy in managing digestive issues and enhancing gastrointestinal health. The product's twice-daily dosing supports individuals with occasional gut discomfort in regaining control over their digestive health. Vegan capsule and free from sweeteners, lactose, and gluten, BioGaia® Gastrus® PURE ACTION is certified as FODMAP-friendly and designed for sensitive stomachs. These are a group of short-chain carbohydrates and sugar alcohols found in many common foods. They are poorly absorbed in the small intestine, leading to fermentation by gut bacteria, which can cause symptoms like bloating, gas, and diarrhea, especially in people with irritable bowel syndrome (IBS) or other digestive sensitivities. A low-FODMAP diet is often recommended by healthcare professionals to manage symptoms of IBS and other functional gastrointestinal disorders. Product availability: Finland is the first country to launch BioGaia® Gastrus® PURE ACTION, with more country launches to follow. In Finland, the product is available in Pharmacies and main online Pharmacies. Supported by clinical research: The product has been tested in clinical trials and proven to be safe and effective in relieving symptoms like abdominal pain, gas, and bloating. Probiotics in this blend are proven to withstand the harsh conditions of digestive system, ensuring they reach gut alive. The efficacy of BioGaia® Gastrus® PURE ACTION's ingredients was recently evaluated in a randomized, double-blind, placebo-controlled trial involving 140 adults aged 18-65, diagnosed with IBS based on Rome IV criteria. Participants who used the product demonstrated: Significant reduction in IBS symptoms: A notable improvement in the GSRS-IBS score from week 6 onward, with key symptoms such as abdominal pain, bloating, and gas showing marked relief. Enhanced Quality of Life: Participants using BioGaia® Gastrus® PURE ACTION reported significantly higher Quality of Life (QoL-IBS) scores compared to those on the placebo. Reduced inflammation: While not a defining feature of IBS, the study showed that Gastrus reduced low-grade gut inflammation. A second study on the same strain combination suggested it also lowered systemic low-grade inflammation. Reported Earnings • Oct 22
Third quarter 2024 earnings released: EPS: kr0.36 (vs kr1.01 in 3Q 2023) Third quarter 2024 results: EPS: kr0.36 (down from kr1.01 in 3Q 2023). Revenue: kr304.0m (down 4.3% from 3Q 2023). Net income: kr36.6m (down 64% from 3Q 2023). Profit margin: 12% (down from 32% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Annonce • Oct 22
BioGaia AB (publ) to Report Q2, 2025 Results on Jul 18, 2025 BioGaia AB (publ) announced that they will report Q2, 2025 results at 8:00 AM, Central European Standard Time on Jul 18, 2025 Recent Insider Transactions • Sep 06
Executive VP & CFO recently sold €996k worth of stock On the 2nd of September, Alexander Kotsinas sold around 95k shares on-market at roughly €10.49 per share. This transaction amounted to 97% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Alexander's only on-market trade for the last 12 months. Reported Earnings • Jul 24
Second quarter 2024 earnings released: EPS: kr1.10 (vs kr0.80 in 2Q 2023) Second quarter 2024 results: EPS: kr1.10 (up from kr0.80 in 2Q 2023). Revenue: kr384.1m (up 22% from 2Q 2023). Net income: kr111.0m (up 38% from 2Q 2023). Profit margin: 29% (up from 26% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Annonce • Jul 23
BioGaia AB (publ) to Report Fiscal Year 2024 Results on Feb 12, 2025 BioGaia AB (publ) announced that they will report fiscal year 2024 results at 8:00 AM, Central European Standard Time on Feb 12, 2025 Reported Earnings • May 07
First quarter 2024 earnings released: EPS: kr1.21 (vs kr1.15 in 1Q 2023) First quarter 2024 results: EPS: kr1.21 (up from kr1.15 in 1Q 2023). Revenue: kr369.8m (up 1.1% from 1Q 2023). Net income: kr121.8m (up 5.1% from 1Q 2023). Profit margin: 33% (up from 32% in 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Mar 26
Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022) Full year 2023 results: EPS: kr3.62 (down from kr3.70 in FY 2022). Revenue: kr1.30b (up 17% from FY 2022). Net income: kr365.4m (down 2.3% from FY 2022). Profit margin: 28% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.8% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Declared Dividend • Feb 12
Dividend of kr6.90 announced Shareholders will receive a dividend of kr6.90. Ex-date: 8th May 2024 Payment date: 15th May 2024 Dividend yield will be 65%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (185% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 19% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 08
Full year 2023 earnings released: EPS: kr3.62 (vs kr3.70 in FY 2022) Full year 2023 results: EPS: kr3.62 (down from kr3.70 in FY 2022). Revenue: kr1.30b (up 17% from FY 2022). Net income: kr365.4m (down 2.3% from FY 2022). Profit margin: 28% (down from 34% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 22
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr317.7m (up 23% from 3Q 2022). Net income: kr101.5m (up 28% from 3Q 2022). Profit margin: 32% (up from 31% in 3Q 2022). The increase in margin was driven by higher revenue. Annonce • Oct 17
Biogaia AB (Publ) Provides Preliminarily Earnings Guidance for Third Quarter 2023 BioGaia AB (publ) provided preliminarily earnings guidance for third quarter 2023. For the third quarter, sales are preliminarily estimated at SEK 318 million, an increase of 23% (excluding foreign exchange effects, 17%). The operating profit for the third quarter is preliminarily estimated at SEK 120 million, an increase of 28%. Annonce • Sep 26
Biogaia AB (Publ) Appoints Theresa Agnew as CEO BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson. Annonce • Sep 02
BioGaia AB (publ) Introduces BioGaia Prodentis KIDS in Sweden BioGaia AB (publ) introduces Prodentis for kids, an apple-flavored lozenge with probiotics and xylitol for oral health, to complement the daily toothbrushing routine. A new addition to the oral health category. Most kids enjoy snacking in between meals, often prefer sugary foods, and have varying enthusiasm for toothbrushing. These habits can lead to unhealthy oral hygiene. Prodentis KIDS contains BioGaia's patented clinically proven probiotic strains L. reuteri ATCC PTA 5289 and L. reuteri DSM 17938 that help the good microorganisms keep a natural balance in the mouth. Prodentis KIDS is specially developed to complement daily toothbrushing routine. From August 2023, Prodentis KIDS will be available for purchase via BioGaia's Swedish webshop, www.biogaia.se as well as the online pharmacies MEDS and Apotea. The recommended retail price is SEK 199. Annonce • Aug 03
BioGaia Appoints Theresa Agnew as New CEO, Effective September 25, 2023 BioGaia's board of directors has appointed Theresa P. Agnew as the new chief executive officer. Theresa Agnew is a global business leader with consumer healthcare, OTC, and medical device experience from leading companies such as GlaxoSmithKline (GSK), Essilor and Johnson & Johnson. She has extensive experience after more than 20 years in leadership roles, managing teams of more than 500 employees. She brings solid international experience having lived and worked in Europe, the US and Australia and the Far East. She has a deep understanding of, and success, in the international healthcare market(s). Theresa holds a B.S. in Biology from Boston College. At GSK she led their OTC global business across multiple segments of Pain Relief, Respiratory Health and Skin Health in OTC pharmaceuticals, naturals, supplements and medical devices in the largest OTC company worldwide. Currently, Theresa Agnew is working at a diabetes start-up, preparing for commercial launch and structuring the company to scale. Theresa Agnew will join the company subject to the successful completion of the pending work permit application process, with an expected starting date as of September 25, or such later date as may be necessary to comply with these requirements. Reported Earnings • Jul 21
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr315.2m (up 9.4% from 2Q 2022). Net income: kr80.5m (up 2.5% from 2Q 2022). Profit margin: 26% (down from 27% in 2Q 2022). The decrease in margin was driven by higher expenses. Annonce • Jul 06
BioGaia's probiotic Protectis increases SARS-CoV-2 antibody response in adults A randomised, triple-blinded, placebo-controlled study with BioGaia's probiotic Protectis was shown to increase SARS-CoV-2 antibody titres in healthy volunteers when 28 days or more had elapsed from vaccination. It suggests that probiotic supplementation may enhance the long-term protection against breakthrough infections. The study included 159 healthy adults without prior SARS-CoV-2 infection or COVID-19 vaccination. The participants consumed either BioGaia Protectis (Limosilactobacillus reuteri DSM 17938) + 10 microgram vitamin D3, or a placebo product that contained only vitamin D3 for 6 months. During the intervention period 12 subjects were infected, and 17 were fully vaccinated and sampled 28 days or more postvaccination. The purpose of the study was to investigate the effect of probiotic supplementation of BioGaia Protectis on SARS-CoV-2 specific antibody responses after natural infection or vaccination. Even though the primary outcome, based on infected subjects, failed to reach a statistically significant difference between the intervention groups, vaccinated individuals who consumed BioGaia Protectis showed significantly increased IgA antibody levels when 28 days or more had elapsed from vaccination. The study was conducted at the Nutrition-Gut-Brain Interactions Research Centre, Örebro University, Sweden. The results suggest that BioGaia Protectis may improve long-term protection against breakthrough infections after vaccination. The same type of antibodies that are increased by probiotics in this study have previously been shown to be protective against breakthrough infections. Board Change • May 15
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Director Niklas Ringby was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • May 07
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr365.8m (up 29% from 1Q 2022). Net income: kr115.9m (up 52% from 1Q 2022). Profit margin: 32% (up from 27% in 1Q 2022). The increase in margin was driven by higher revenue. Upcoming Dividend • May 01
Upcoming dividend of kr2.90 per share at 2.8% yield Eligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (2.4%). Reported Earnings • Mar 31
Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021) Full year 2022 results: EPS: kr3.70 (up from kr1.94 in FY 2021). Revenue: kr1.10b (up 41% from FY 2021). Net income: kr373.8m (up 90% from FY 2021). Profit margin: 34% (up from 25% in FY 2021). Post-clinical trial products Launched (during full year): 3 Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 05
Full year 2022 earnings released: EPS: kr3.70 (vs kr1.94 in FY 2021) Full year 2022 results: EPS: kr3.70 (up from kr1.94 in FY 2021). Revenue: kr1.10b (up 41% from FY 2021). Net income: kr373.6m (up 90% from FY 2021). Profit margin: 34% (up from 25% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.9% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 22
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr257.7m (up 48% from 3Q 2021). Net income: kr79.5m (up 50% from 3Q 2021). Profit margin: 31% (in line with 3Q 2021). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment improved over the past week After last week's 21% share price gain to €8.37, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 23% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €5.22 per share. Annonce • Oct 17
BioGaia AB (publ) Provides Earnings Guidance for the Third Quarter of 2022 BioGaia AB (publ) provided earnings guidance for the third quarter of 2022. For the third quarter, sales are preliminarily estimated at SEK 258 million (174), an increase of 48%. The operating profit for the third quarter is preliminarily estimated at SEK 94 million (67), an increase of 40%. Valuation Update With 7 Day Price Move • Jul 29
Investor sentiment deteriorated over the past week After last week's 18% share price decline to €8.82, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 30x in the Biotechs industry in Europe. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.92 per share. Reported Earnings • Jul 25
Second quarter 2022 earnings released: EPS: kr0.78 (vs kr0.54 in 2Q 2021) Second quarter 2022 results: EPS: kr0.78 (up from kr0.54 in 2Q 2021). Revenue: kr288.1m (up 42% from 2Q 2021). Net income: kr78.5m (up 44% from 2Q 2021). Profit margin: 27% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 9.2%, compared to a 31% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Annonce • Jul 14
Biogaia AB (publ) Provides Earnings Guidance for the Second Quarter of 2022 BioGaia AB (publ) provided earnings guidance for the second quarter of 2022. For the period, Sales are preliminarily estimated at SEK 288 million (203), up 42% and Operating profit is preliminarily estimated at SEK 101 million (69), up 46%. Annonce • May 08
BioGaia AB (publ) Approves Extra Dividend The Annual General Meeting of BioGaia AB (publ) on 6 May 2022 voted to approve a dividend an extra dividend of SEK 11.29 per share. Reported Earnings • May 07
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr283.9m (up 41% from 1Q 2021). Net income: kr76.3m (up 51% from 1Q 2021). Profit margin: 27% (up from 25% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 37% growth forecast for the industry in Germany. Upcoming Dividend • May 02
Upcoming dividend of kr14.92 per share Eligible shareholders must have bought the stock before 09 May 2022. Payment date: 13 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.5%). Annonce • Apr 26
BioGaia AB (publ) Provides Earnings Guidance for the First Quarter of 2022 BioGaia AB (publ) provided earnings guidance for the first quarter of 2022. For the quarter, the company sales are preliminarily estimated at SEK 284 million. Operating profit is preliminarily estimated at SEK 95 million. Reported Earnings • Mar 31
Full year 2021 earnings released: EPS: kr9.72 (vs kr10.07 in FY 2020) Full year 2021 results: EPS: kr9.72. Revenue: kr785.1m (up 5.1% from FY 2020). Net income: kr196.3m (up 9.2% from FY 2020). Profit margin: 25% (in line with FY 2020). Over the next year, revenue is forecast to grow 24%, compared to a 86% growth forecast for the pharmaceuticals industry in Germany. Annonce • Feb 03
BioGaia's Probiotic Reduces Inflammation in Patients with Diverticulitis A randomized, double-blind, placebo-controlled study with BioGaia's probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 was shown to reduce inflammation significantly more than placebo in patients with acute uncomplicated diverticulitis. Moreover, as hospitalization time was shorter in the probiotic group, the probiotic supplementation also had economic benefits. The study included 119 patients, 49 males and 70 females, diagnosed with acute uncomplicated diverticulitis. Mean age was 65 years. All patients were given fluids and bowel rest for 48 hours. Half of the group were additionally supplemented by Limosilactobacillus reuteri ATCC PTA 4659 for 10 days, while the other half were given a placebo. BioGaia's probiotic strain Limosilactobacillus reuteri ATCC PTA 4659 has in experimental models shown strong anti-inflammatory properties, indicating potential positive effects in inflammatory conditions of the intestine. The now published study is the first randomized, double-blind, placebo-controlled study using this anti-inflammatory strain for acute uncomplicated diverticulitis without any antibiotic therapy. It is common, especially after the age of 40, to have small, bulging pouches in the lining of the digestive tract. The condition known as diverticulitis occurs when one or more of these pouches become inflamed or infected, something that can cause severe abdominal pain, but also fever, nausea, and changes in bowel habits. Annonce • Jan 26
BioGaia AB (publ) Announces First Patient Enrolled in Phase II Clinical Study Evaluating BGP345A for the Treatment of Opioid Induced Constipation (OIC-1) BioGaia Pharma received formal approval from relevant authorities to proceed with both of its planned clinical trials during summer 2021. Investigational Medical Products were delivered to sites fourth quarter 2021 and screening began. The first patient was enrolled into OIC-1 in January 2022. BGP345A looks to treat constipation in patients receiving opioid therapy for prescribed pain treatment. Opioids are an essential option for chronic pain, primarily back pain, rheumatism or post-operative pain, where non-opioid multimodal drugs or physical therapy are not providing relief. Opioid use can lead to a number of side effects with Opioid-Induced Constipation (OIC) being the most common with a varying prevalance of 41-81%. Current first line therapy is the use of laxatives but at least 45% of patients are laxative refractory and continue to have motility issues. The approved study is a Phase II multi-centre study to assess the safety and preliminary efficacy of BGP345A and will take place in France. Reported Earnings • Oct 22
Third quarter 2021 earnings released The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr173.8m (up 32% from 3Q 2020). Net income: kr52.8m (up 158% from 3Q 2020). Profit margin: 30% (up from 16% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Reported Earnings • Aug 13
Second quarter 2021 earnings released: EPS kr2.71 (vs kr4.56 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr203.1m (down 17% from 2Q 2020). Net income: kr54.7m (down 31% from 2Q 2020). Profit margin: 27% (down from 32% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Annonce • Jul 03
BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million. BioGaia AB (publ) (OM:BIOG B) acquired remaining 8% stake in MetaboGen AB for SEK 11.4 million on July 2, 2021. Upon completion, BioGaia becomes 100% shareholder of MetaboGen.
BioGaia AB (publ) (OM:BIOG B) completed the acquisition of remaining 8% stake in MetaboGen AB on July 2, 2021. Recent Insider Transactions • Jun 01
Vice President of RA & Legal recently bought €10k worth of stock On the 27th of May, Marika Isberg bought around 250 shares on-market at roughly €40.52 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €19k more in shares than they have sold in the last 12 months. Annonce • May 07
Biogaia AB (Publ) Approves Dividend The Annual General Meeting of BioGaia AB (publ) held on 6 May 2021, approved the dividend of SEK 3.41 per share. Reported Earnings • May 06
First quarter 2021 earnings released The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: kr202.0m (up 11% from 1Q 2020). Net income: kr50.4m (up 21% from 1Q 2020). Profit margin: 25% (up from 23% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 30
Upcoming dividend of kr3.41 per share Eligible shareholders must have bought the stock before 07 May 2021. Payment date: 14 May 2021. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (3.1%). Higher than average of industry peers (0.5%). Reported Earnings • Apr 04
Full year 2020 earnings released: EPS kr10.07 The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr747.1m (down 2.8% from FY 2019). Net income: kr179.7m (down 4.1% from FY 2019). Profit margin: 24% (in line with FY 2019). Post-clinical trial products Launched (during full year): 18 Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year. Is New 90 Day High Low • Feb 20
New 90-day low: €43.00 The company is down 4.0% from its price of €44.70 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.41 per share. Recent Insider Transactions • Feb 12
CEO & President recently bought €9.8k worth of stock On the 4th of February, Isabelle Valerie Ducellier bought around 220 shares on-market at roughly €44.43 per share. This was the largest purchase by an insider in the last 3 months. Isabelle Valerie has been a buyer over the last 12 months, purchasing a net total of €56k worth in shares. Reported Earnings • Feb 06
Full year 2020 earnings released: EPS kr10.07 (vs kr10.81 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr747.1m (down 2.8% from FY 2019). Net income: kr179.7m (down 4.1% from FY 2019). Profit margin: 24% (in line with FY 2019). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Feb 06
Revenue beats expectations Revenue exceeded analyst estimates by 0.5%. Over the next year, revenue is forecast to grow 4.6%, compared to a 80% growth forecast for the Biotechs industry in Germany. Annonce • Nov 26
BioGaia AB (publ) Elects Niklas Ringby as New Board Member BioGaia AB (publ) announced at its Extraordinary General Meeting was held on 25 November 2020, the shareholders elected Niklas Ringby as new Board member. Valuation Update With 7 Day Price Move • Nov 05
Market bids up stock over the past week After last week's 19% share price gain to kr48.90, the stock is trading at a trailing P/E ratio of 44.8x, up from the previous P/E ratio of 37.6x. This compares to an average P/E of 30x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 62%. Annonce • Oct 31
BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion. BioGaia AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.144 billion.
Security Name: B Shares
Security Type: Common Stock
Securities Offered: 2,860,000
Price\Range: SEK 400 Reported Earnings • Oct 24
Third quarter earnings released Over the last 12 months the company has reported total profits of kr193.8m, up 1.0% from the prior year. Total revenue was kr767.1m over the last 12 months, largely unchanged from the prior year. Analyst Estimate Surprise Post Earnings • Oct 24
Third-quarter earnings released: Revenue misses expectations Third-quarter revenue missed analyst estimates by 29% at kr132.0m. Revenue is forecast to grow 18% over the next year, compared to a 301% growth forecast for the Biotechs industry in Germany. Valuation Update With 7 Day Price Move • Oct 19
Market pulls back on stock over the past week After last week's 21% share price decline to kr44.05, the stock is trading at a trailing P/E ratio of 37.6x, down from the previous P/E ratio of 47.9x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 57%. Is New 90 Day High Low • Oct 16
New 90-day low: €43.55 The company is down 17% from its price of €52.40 on 17 July 2020. The German market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.89 per share. Valuation Update With 7 Day Price Move • Oct 16
Market pulls back on stock over the past week After last week's 18% share price decline to kr43.55, the stock is trading at a trailing P/E ratio of 38.1x, down from the previous P/E ratio of 46.4x. This compares to an average P/E of 36x in the Biotechs industry in Europe. Total returns to shareholders over the past three years are 55%. Annonce • Oct 05
Biogaia Announces L. reuteri Protectis Reduces Pain in Children with Functional Abdominal Pain In a newly published systematic review and meta-analysis BioGaia AB (publ)'s L.reuteri Protectis (DSM 17938) was the only probiotic showing reduced pain intensity as well as an increased number of pain free days compared to placebo, in children with functional abdominal pain (FAP). Even if functional abdominal pain is a common gastrointestinal disorder, there are still no adequate treatment options available. The aim of the systematic review and meta-analysis was therefore to evaluate strain-specific probiotic effects on functional abdominal pain in children. The meta-analysis included nine studies, of which six were conducted with L. reuteri DSM 17938 and three with L. rhamnosus GG (LGG). The primary outcome, number of children with no symptoms at end of intervention, was however not reached. 
